Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash-to-Debt 0.32
HH's Cash-to-Debt is ranked lower than
54% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 0.40 vs. HH: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
HH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 12.26 Max: No Debt
Current: 0.32
Equity-to-Asset -0.20
HH's Equity-to-Asset is ranked lower than
96% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. HH: -0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
HH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.2  Med: 0.65 Max: 0.91
Current: -0.2
-0.2
0.91
Piotroski F-Score: 4
Altman Z-Score: -16.58
Beneish M-Score: -4.47
WACC vs ROIC
13.32%
-190.93%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -21.11
HH's Operating Margin % is ranked lower than
94% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. HH: -21.11 )
Ranked among companies with meaningful Operating Margin % only.
HH' s Operating Margin % Range Over the Past 10 Years
Min: -50.4  Med: -17.51 Max: 0.14
Current: -21.11
-50.4
0.14
Net Margin % -30.12
HH's Net Margin % is ranked lower than
94% of the 256 Companies
in the Global Medical Care industry.

( Industry Median: 4.84 vs. HH: -30.12 )
Ranked among companies with meaningful Net Margin % only.
HH' s Net Margin % Range Over the Past 10 Years
Min: -79.5  Med: -29.71 Max: 0.89
Current: -30.12
-79.5
0.89
ROA % -63.47
HH's ROA % is ranked lower than
98% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 4.66 vs. HH: -63.47 )
Ranked among companies with meaningful ROA % only.
HH' s ROA % Range Over the Past 10 Years
Min: -70.56  Med: -24.26 Max: 2.59
Current: -63.47
-70.56
2.59
ROC (Joel Greenblatt) % -375.71
HH's ROC (Joel Greenblatt) % is ranked lower than
96% of the 257 Companies
in the Global Medical Care industry.

( Industry Median: 21.13 vs. HH: -375.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -392.94  Med: -53.07 Max: 6.95
Current: -375.71
-392.94
6.95
3-Year Revenue Growth Rate -9.70
HH's 3-Year Revenue Growth Rate is ranked lower than
87% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 8.50 vs. HH: -9.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -50.6  Med: 0.2 Max: 19.3
Current: -9.7
-50.6
19.3
3-Year EBITDA Growth Rate -31.50
HH's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 161 Companies
in the Global Medical Care industry.

( Industry Median: 8.10 vs. HH: -31.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
HH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -31.5  Med: 3.4 Max: 37.9
Current: -31.5
-31.5
37.9
3-Year EPS without NRI Growth Rate -25.60
HH's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 8.40 vs. HH: -25.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.8 Max: 97.3
Current: -25.6
0
97.3
GuruFocus has detected 4 Warning Signs with Hooper Holmes Inc $HH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HH's 10-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

HH Guru Trades in Q1 2016

Jim Simons 1,198,300 sh (+7.67%)
» More
Q2 2016

HH Guru Trades in Q2 2016

Jim Simons 91,229 sh (+14.20%)
» More
Q3 2016

HH Guru Trades in Q3 2016

Jim Simons 91,729 sh (+0.55%)
» More
Q4 2016

HH Guru Trades in Q4 2016

Jim Simons 63,329 sh (-30.96%)
» More
» Details

Insider Trades

Latest Guru Trades with HH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 524291    SIC: 6411
Compare:OTCPK:BRRZF, OTCPK:LMNK, OTCPK:WNDM, OTCPK:QNIIF, OTCPK:PFHO, OTCPK:SPIN, OTCPK:AGHEF, OTCPK:JRSS, OTCPK:GRST, AMEX:SSY, OTCPK:USNU, OTCPK:CVHIF, OTCPK:BNKL, OTCPK:CAMDF, AMEX:AMS, OTCPK:BICX, OTCPK:ARPC, OTCPK:CCEL, OTCPK:ADPTQ, OTCPK:FCHS » details
Headquarter Location:USA
Hooper Holmes Inc provides on-site health screenings, laboratory testing, risk assessment and sample collection services to individuals as part of comprehensive health and wellness programs offered through corporate and government employers.

Hooper Holmes Inc provides medical and other underwriting information on insurance policy applicants to life and health insurance companies. Through its network of more than 300 offices in the United States, the company provides medical examinations, personal health interviews, medical record collection, and laboratory testing, which help insurance companies evaluate the risks associated with their underwriting policies. Hooper Holmes has more than 700 insurance company customers.

Top Ranked Articles about Hooper Holmes Inc

Hooper Holmes Selected by Paradigm Health Plans for Biometric Screenings
Hooper Holmes Announces Plans to Move the Listing of its Shares to the OTCQX Marketplace
Hooper Holmes Files 2016 Annual Report on Form 10-K and Form S-4 Regarding Proposed Merger with Provant Health Solutions
— Affirms Outlook Following Merger Announcement
— Executing Well for Long-Term Growth
OLATHE, Kan., March 20, 2017 (GLOBE NEWSWIRE) -- Hooper Holmes Inc. (:HH) has filed its Annual Report on Form 10-K for the year ended December 31, 2016, and Form S-4 related to the Company's proposed merger with Provant Health Solutions LLC, with the Securities and Exchange Commission (“SEC”).As reported in the Company's Annual Report, Hooper’s adjusted EBITDA for the 2016 fourth quarter improved by 65% compared to the same period in 2015. For the full year 2016, the Company’s adjusted EBITDA was negative $3.1 million, reflecting an improvement of $1.2 million, or 28% from the prior year. "We believe continued improvements in our adjusted EBITDA demonstrate the benefits of driving to scale, which we anticipate will accelerate upon completion of our merger with Provant. Further, our clients have reacted positively to the merger announcement. We are enthusiastic about our prospects as a combined company, with scale, growth and synergies expected to significantly improve operating cash flow," said Henry E. Dubois, President and CEO of Hooper Holmes.On March 8, 2017, the Company announced an agreement to combine with Provant Health Solutions LLC in an all-stock transaction which will create one of the largest, pure-play health and wellness companies in the United States.   Since announcing the pending merger with Provant, Hooper Holmes has filed a Form S-4 proxy statement for review by the SEC in preparation for a special shareholders' meeting to approve the merger. In this filing, the Company reported that, on a pro-forma basis as if combined, 2016 revenues for the two companies were $67 million, net of gift-card pass-through revenue.Once the Form S-4 has been reviewed by the SEC and becomes effective, the Company anticipates closing the merger at the end of April or in early May 2017, pursuant to the approval of Hooper Holmes’ shareholders.Financing to support the merger transaction and provide working capital has been arranged from SWK Holdings, a specialized finance company focused on the healthcare sector, through a $6.5 million, five-year term loan at LIBOR plus 12.5%, a reduction of 150 basis points from Hooper's current term facility. The Company has also expanded its current asset-based credit facility from $7 million to $10 million with an accordion to $15 million during high-volume months. Both of Hooper’s current lenders are participating in this transaction and are providing sufficient working capital to support integration and growth.The Company’s audit opinion in the Form 10-K for the year ended December 31, 2016, included a going concern clarifying statement as it did in 2015. The Company will continue to monitor its liquidity carefully and work to reduce this uncertainty.Copies of the Annual Report on Form 10-K and the Form S-4 are available to be viewed or downloaded at www.hooperholmes.com/investors.About Hooper HolmesHooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs. www.hooperholmes.comAbout ProvantProvant is a leader of comprehensive workplace well-being solutions in North America, with a growing global presence. Founded in 2001, Provant partners with employers to improve employee health and productivity while supporting healthcare cost management. Through a network of 13,000 health professionals, Provant touches millions of lives by delivering customized well-being strategies and services on-site, telephonically and digitally utilizing advanced data management. Provant is a privately held company headquartered in East Greenwich, Rhode Island. www.provanthealth.comAdditional Information about the Proposed Merger and Where to Find It
In connection with the previously disclosed proposed merger with Provant, the Company has filed a registration statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), including a proxy statement/prospectus, but the registration statement has not yet become effective. Shareholders of the Company are urged to read these materials because they contain important information about the Company, Provant, and the proposed merger. The proxy statement/prospectus and other documents filed by the Company with the SEC may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by the Company by directing a written request to: Hooper Holmes, Inc., 560 N. Rogers Road, Olathe, Kansas 66062, Attention: Legal Department. Shareholders of the Company are urged to read the proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed merger. This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. Participants in the Solicitation The Company and its directors and executive officers and Provant and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the proposed merger. Information regarding the special interests of these directors and executive officers in the merger is included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of the Company is also included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, which is available free of charge at the SEC web site (www.sec.gov) and from the Company at the address described above.This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intends," "plan," and "will" or, in each case, their negative, and other variations or comparable terminology. These forward-looking statements include all statements other than historical facts. Any forward-looking statement made by management during this call is not a guarantee of future performance, and actual results may differ materially from those expressed in or suggested by the forward-looking statements, as a result of various factors, including, without limitation the factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2016, as the same may be updated from time-to-time in subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made by management on this call speaks only as of the date hereof, and the Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. In addition, management uses the non-GAAP performance measures EBITDA and Adjusted EBITDA in this press release. 
For further information:

Hooper Holmes
Henry E. Dubois
President and CEO
(913) 764-1045

Investors: Andrew Berger
S.M. Berger & Company
(216) 464-6400

Investors: Scott Gordon
CORE IR
(516) 222-2560

Read more...
Dr. Robin Smith Joins Hooper Holmes as a Board Advisor

OLATHE, Kan., March 16, 2017 (GLOBE NEWSWIRE) -- Hooper Holmes, Inc. (:HH) is pleased to welcome Robin L. Smith, M.D. as a board advisor to assist with the assessment of strategic expansion opportunities in the health and well-being market.
“As we prepare to merge with Provant Health Solutions, LLC and continue to create one of the largest, pure-play health and wellness companies in the U.S., we welcome Dr. Smith as a board advisor,” said Henry Dubois, President and CEO of Hooper Holmes. “Dr. Smith’s expertise in healthcare and innovative clinical-based solutions, as well as her strong track record building, leading and assisting a variety of organizations and companies will provide additional insight on new products and potential services the Company can offer to clients to drive increased revenues and margins.  I look forward to working closely with Dr. Smith as we focus on profitably growing our business.” Dr. Smith added, “As the health and wellness market continues to grow, employers and insurers are looking for ‘value based’ care, Hooper Holmes has a compelling market opportunity.  I look forward to collaborating with the team to expand their health and well-being solutions to reduce the chronic disease epidemic our country is facing and empower employees to improve their individual health.” Dr. Smith has vast experience in a multitude of leadership and strategic roles and is a renowned global thought leader in the regenerative medicine industry, one of the fastest growing segments of modern-day medicine.  Dr. Robin L. Smith received her M.D. from Yale University and an M.B.A. from the Wharton School of Business. She maintains a regular column on these topics for The Huffington Post and is the recipient of many accolades including the 2014 SmartCEO Brava! Award, which recognizes top women business leaders in the Greater New York area. She was also a finalist for the 2014 EY Entrepreneur of the Year award for the New York area, recognizing entrepreneurs who demonstrate excellence and success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Dr. Smith has extensive history serving in executive and board level capacities for various medical enterprises and healthcare-based entities.  She founded and has served as Chairman of the Board and President of The Stem for Life Foundation (SFLF) since its inception, an organization which is devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions.  She is expanding SFLF’s mission further under the Cura Foundation where she serves as President and Chairman.  Their efforts are focused on bringing resources to fund cell therapy clinical trials and assist in accelerating enrollment and completion.  Dr. Smith also serves as Chairman for MYnd Analytics, Inc., a predictive analytics company that developed a decision support system to help physicians reduce trial and error treatment in mental health.  Recently Hooper Holmes and MYnd Analytics announced a strategic partnership whereby the Hooper Holmes national network of health professionals will provide on-site or in-home EEG services for MYnd Analytics nationally. About Hooper Holmes Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs. www.hooperholmes.com  This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intends," "plan," and "will" or, in each case, their negative, and other variations or comparable terminology.  These forward-looking statements include all statements other than historical facts.   Any forward-looking statement made by management during this call is not a guarantee of future performance, and actual results may differ materially from those expressed in or suggested by the forward-looking statements, as a result of various factors, including, without limitation the factors discussed in the "Risk Factors" section of the company's Annual Report on Form 10-K for the year ended December 31, 2016, as the same may be updated from time-to-time in subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made by management on this call speaks only as of the date hereof, and the Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. In addition, management uses the non-GAAP performance measures EBITDA and Adjusted EBITDA in this press release.  

For further information:

Hooper Holmes
Henry E. Dubois
President and CEO
(913) 764-1045

Investors: Andrew Berger
S.M. Berger & Company
(216) 464-6400

Investors: Scott Gordon
CORE IR
(516) 222-2560

Read more...
Hooper Holmes and Provant to Merge

All-stock, accretive transaction increasing scale and enhancing scope Pro-forma 2016 revenue of $67 millionProvides scale and significant cost saving synergiesFinancing in place to support transaction and working capitalStrength of product offering and diversification of distribution channels accelerates innovation for existing customers and growth Expected to close in 2017 second quarter OLATHE, Kan. and EAST GREENWICH, R.I., March 08, 2017 (GLOBE NEWSWIRE) -- Hooper Holmes Inc. (:HH) and Provant Health Solutions LLC have agreed to combine in an all-stock transaction which will create one of the largest, pure-play health and wellness companies in the United States. On a combined basis, 2016 pro-forma annual revenue of the merged company is approximately $67 million, excluding $3.8 million of pass-through gift card revenue at Provant. This transaction is expected to significantly improve financial performance, expand the merged company’s combined national network of local health professionals and advance its well-being solutions technology. “Scale, growth and synergies will create a compelling financial model and are expected to improve operating cash flow for our merged company. Our channel partners will be supported by an expanded network of local health professionals and direct customers will gain access to an expanded suite of personalized digital services that promote, track and measure healthy behaviors and outcomes,” said Henry E. Dubois, Chief Executive Officer of Hooper Holmes. “Combining Hooper’s market-leading clinical services with Provant’s expertise in member service, personalized well-being and advanced analytics will deepen collaboration with our customers and channel partners,” said Heather Provino, Chief Executive Officer and founder of Provant. “Best-in-class, strategic partnerships are essential for capitalizing on the massive opportunity our industry is seeing in order to take advantage of the paradigm shift occurring in consumerism. We believe this powerful combination will drive innovation for our clients and accelerate growth.” The transaction has compelling strategic and financial benefits for both health and wellness solutions companies. Provant and Hooper represent an exceptionally synergistic merger, bringing together unique specialties that cross business verticals. The merged company will be highly focused on leveraging each company's expertise to maximize growth, broaden market appeal and provide additional value that aligns with the objectives of clients and channel partners. The two companies have no customer overlap and both target growing healthcare market segments. Synergies from leveraging fixed costs and optimizing services and processes are expected to significantly reduce the merged company’s cost structure, supporting a more efficient organization. The merger is expected to be accretive to adjusted EBITDA in full year 2017. Under the terms of the transaction Hooper Holmes will issue approximately 10.5 million shares of common stock to Provant's owners and the merged company will raise $3.5 million in new equity capital. Century Equity Partners, the majority shareholder of Provant, has committed to $1.75 million of the $3.5 million equity raise and certain existing Hooper shareholders and insiders have committed to an additional $1.6 million, for a total of $3.3 million of the $3.5 million already committed. Financing Financing to support the transaction and provide working capital has been arranged from SWK Holdings, a specialized finance company focused on the healthcare sector, through a $6.5 million, five year term loan at LIBOR plus 12.5%, a reduction of 150 basis points from Hooper's current term facility. Principal repayments start in the first quarter of 2019. The company has also expanded its current asset-based credit facility from $7 million to $10 million with an accordion to $15 million during high-volume months. Both of Hooper’s current lenders are participating in this transaction and are providing sufficient working capital to support integration and growth. At close, the merged company is expected to have cash on hand of $2-3 million and $10-12 million in receivables. Management and Governance Upon closing, Henry Dubois will serve as Chief Executive Officer of the merged company and Heather Provino will serve as Chief Strategy Officer. Further maintaining strength in leadership, Mark Clermont of Provant will serve as President and Steven Balthazor of Hooper Holmes will  serve as Chief Financial Officer. The Board of Directors will consist of seven members, three of which will be current Hooper Holmes directors, three of which will be current Provant directors and one independent director who currently chairs Hooper's audit committee. The company will continue to trade under the HH stock symbol. The company will have two major locations in Olathe, Kansas and East Greenwich, Rhode Island. Approvals and Time to Close The company expects to file a Form S-4 within the next ten days. Once the S-4 is effective, shareholder approval of the transaction is anticipated in 30 days. Closing is anticipated in late April or early May 2017. Advisors Cantor Fitzgerald has advised Hooper Holmes. Raymond James has advised Provant. Conference Call and Webcast The Company will host a conference call today, Wednesday, March 8, 2017, at 7:30 a.m. CT (8:30 a.m. ET) to discuss the merger. A slide presentation will accompany the conference call and is available on the Company’s website located at www.hooperholmes.com. To participate in the conference call, please dial (888) 349-9586 or internationally 1-719-325-2247, conference ID: 4925972, five to ten minutes before the call is scheduled to begin. A live webcast will be hosted on the Company's website located at www.hooperholmes.com. A replay of the conference call will be available through March 15, 2017 by dialing (844) 512-2921, or internationally 1-412-317-6671. The access code for the replay is 4925972. About Hooper Holmes Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs. www.hooperholmes.com About Provant Provant is a leader of comprehensive workplace well-being solutions in North America, with a growing global presence. Founded in 2001, Provant partners with employers to improve employee health and productivity while supporting healthcare cost management. Through a network of 13,000 health professionals, Provant touches millions of lives by delivering customized well-being strategies and services on-site, telephonically and digitally utilizing advanced data management. Provant is a privately held company headquartered in East Greenwich, Rhode Island. www.provanthealth.com This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intends," "plan," and "will" or, in each case, their negative, and other variations or comparable terminology.  These forward-looking statements include all statements other than historical facts.   Any forward-looking statement made by management during this call is not a guarantee of future performance, and actual results may differ materially from those expressed in or suggested by the forward-looking statements, as a result of various factors, including, without limitation the factors discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2015, as the same may be updated from time-to-time in subsequent filings with the Securities and Exchange Commission. Any forward-looking statement made by management on this call speaks only as of the date hereof, and the Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. In addition, management uses the non-GAAP performance measures EBITDA and Adjusted EBITDA in this press release.
For further information:

Hooper Holmes
Henry E. Dubois
President and CEO
(913) 764-1045

Provant
Heather Provino
CEO
(401) 234-1700

Investors: Andrew Berger
S.M. Berger & Company
(216) 464-6400

Investors: Scott Gordon
CORE IR
(516) 222-2560

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.21
HH's PS Ratio is ranked higher than
95% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.57 vs. HH: 0.21 )
Ranked among companies with meaningful PS Ratio only.
HH' s PS Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.4 Max: 5.58
Current: 0.21
0.06
5.58
EV-to-EBIT -1.80
HH's EV-to-EBIT is ranked lower than
99.99% of the 292 Companies
in the Global Medical Care industry.

( Industry Median: 18.39 vs. HH: -1.80 )
Ranked among companies with meaningful EV-to-EBIT only.
HH' s EV-to-EBIT Range Over the Past 10 Years
Min: -160.1  Med: -2.9 Max: 30.7
Current: -1.8
-160.1
30.7
EV-to-EBITDA -2.71
HH's EV-to-EBITDA is ranked lower than
99.99% of the 306 Companies
in the Global Medical Care industry.

( Industry Median: 13.46 vs. HH: -2.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
HH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -103.8  Med: -2.8 Max: 16.1
Current: -2.71
-103.8
16.1
Current Ratio 0.45
HH's Current Ratio is ranked lower than
91% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.30 vs. HH: 0.45 )
Ranked among companies with meaningful Current Ratio only.
HH' s Current Ratio Range Over the Past 10 Years
Min: 0.45  Med: 2.86 Max: 7.23
Current: 0.45
0.45
7.23
Quick Ratio 0.38
HH's Quick Ratio is ranked lower than
91% of the 244 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. HH: 0.38 )
Ranked among companies with meaningful Quick Ratio only.
HH' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.86 Max: 7.23
Current: 0.38
0.38
7.23
Days Inventory 13.33
HH's Days Inventory is ranked higher than
59% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: 16.88 vs. HH: 13.33 )
Ranked among companies with meaningful Days Inventory only.
HH' s Days Inventory Range Over the Past 10 Years
Min: 5.19  Med: 11.02 Max: 42.22
Current: 13.33
5.19
42.22
Days Sales Outstanding 44.25
HH's Days Sales Outstanding is ranked lower than
55% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. HH: 44.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
HH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.67  Med: 46.1 Max: 280.61
Current: 44.25
40.67
280.61
Days Payable 91.36
HH's Days Payable is ranked higher than
70% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: 40.41 vs. HH: 91.36 )
Ranked among companies with meaningful Days Payable only.
HH' s Days Payable Range Over the Past 10 Years
Min: 14.15  Med: 46.22 Max: 162.88
Current: 91.36
14.15
162.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -29.10
HH's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. HH: -29.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.1  Med: -1.7 Max: 0.7
Current: -29.1
-29.1
0.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.50
HH's Price-to-Median-PS-Value is ranked higher than
92% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 1.04 vs. HH: 0.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.51 Max: 8.29
Current: 0.5
0.21
8.29
Earnings Yield (Greenblatt) % -55.04
HH's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 334 Companies
in the Global Medical Care industry.

( Industry Median: 4.98 vs. HH: -55.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -57.59  Med: 5.55 Max: 8.3
Current: -55.04
-57.59
8.3
Forward Rate of Return (Yacktman) % 646.84
HH's Forward Rate of Return (Yacktman) % is ranked higher than
99% of the 119 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. HH: 646.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.8  Med: -0.2 Max: 646.84
Current: 646.84
-0.8
646.84

More Statistics

Revenue (TTM) (Mil) $34.27
EPS (TTM) $ -1.18
Beta1.40
Short Percentage of Float2.09%
52-Week Range $0.65 - 2.70
Shares Outstanding (Mil)12.16
» More Articles for HH

Headlines

Articles On GuruFocus.com
Hooper Holmes Selected by Paradigm Health Plans for Biometric Screenings Apr 24 2017 
Hooper Holmes Announces Plans to Move the Listing of its Shares to the OTCQX Marketplace Apr 20 2017 
Hooper Holmes Files 2016 Annual Report on Form 10-K and Form S-4 Regarding Proposed Merger with Prov Mar 20 2017 
Dr. Robin Smith Joins Hooper Holmes as a Board Advisor Mar 16 2017 
Hooper Holmes and Provant to Merge Mar 08 2017 
Arquitos Capital Management Q1 2015 Investor Letter May 01 2015 
Hooper Holmes Inc Reports Operating Results (10-Q) Nov 05 2010 
Hooper Holmes Inc Reports Operating Results (10-Q) Aug 06 2010 
Hooper Holmes Inc Reports Operating Results (10-Q) May 07 2010 
Hooper Holmes Inc Reports Operating Results (10-Q) Nov 06 2009 

More From Other Websites
Hooper Holmes Selected by Paradigm Health Plans for Biometric Screenings Apr 24 2017
Hooper Holmes Announces Plans to Move the Listing of its Shares to the OTCQX Marketplace Apr 20 2017
Hooper Holmes Files 2016 Annual Report on Form 10-K and Form S-4 Regarding Proposed Merger with... Mar 20 2017
Henry E. Dubois, CEO of Hooper Holmes Inc., (NYSE: HH) to Present at The MicroCap Conference on... Mar 20 2017
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Hooper Holmes, Inc. - HH Mar 17 2017
Hooper Holmes, Inc. :HH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Mar 16 2017
Dr. Robin Smith Joins Hooper Holmes as a Board Advisor Mar 16 2017
Blog Coverage Hooper Holmes Acquires Privately Held Health and Wellness Company Provant Health... Mar 09 2017
Olathe wellness company merges with Rhode Island peer Mar 08 2017
Hooper Holmes and Provant to Merge Mar 08 2017
Hooper Holmes to Present at the 9th Annual LD Micro Main Event Nov 29 2016
Hooper Holmes, Inc. :HH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Edited Transcript of HH earnings conference call or presentation 10-Nov-16 1:30pm GMT Nov 10 2016
Hooper Holmes, Inc. :HH-US: Earnings Analysis: Q2, 2016 By the Numbers : October 4, 2016 Oct 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)